Glaukos is a medical device company located in California, United States, which is part of the Healthcare sector, and is traded under the ticker GKOS on the NYSE exchange.
Glaukos stock last closed at $245.72, down 0.13% from the previous day, and has increased 167.64% in one year. It has overperformed other stocks in the Medical Devices industry by 2.59 percentage points. Glaukos stock is currently +181.4% from its 52-week low of $87.32, and -3.71% from its 52-week high of $255.19.
There are currently 59.2M shares of GKOS outstanding. The market value of GKOS is $14.55B. In the past 24 hours, 546,000 GKOS shares were traded.
How to Buy Glaukos Stock
Wondering how to invest in Glaukos stock? Here's how.
Decide where to buy Glaukos stock: You need to choose a stock brokerage, but don't worry - we've tested dozens of stock brokerages and apps to help you figure out where to buy Glaukos stock.
Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit funds into your investment account: Select your method of payment and add your info.
Evaluate Glaukos stock: The Glaukos ticker symbol is GKOS. Is Glaukos stock a good investment? Should you buy shares of GKOS? How do GKOS's underlying business fundamentals look? Do top analysts think Glaukos is a good buy? Why has GKOS's stock price moved recently? (Hint: Our stock market analysis tools can help you figure out if GKOS is a good stock to buy).
Make your GKOS purchase: Decide if you will purchase GKOS shares at the current market price or use a limit order to buy GKOS stock at a specific price.
Get updates on your GKOS position: Create a watchlist to important updates regarding your investment in Glaukos shares.
Step 1: Decide where to buy Glaukos stock
You will need an online brokerage account in order to access the NYSE market and buy GKOS shares.
A brokerage account is an investment account that allows you to buy and sell a variety of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. eToro gives you:
You can invest in stocks with 0% commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
Access to world financial markets: From Tech to Healthcare, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the world's top stock exchanges.
Social investing: eToro has a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
Security: eToro is a regulated and licensed fintech leader.
Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of shares by signing up for an account with eToro today. This offer is only for US users.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Create your brokerage account
Now that you've chosen the best brokerage, you'll need to fill out some personal details so you can invest in GKOS stock today.
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
Step 4: Evaluate Glaukos stock
After you have chosen the best place to buy Glaukos stock, it's absolutely critical to analyze their stock before you invest, so you can comprehend the risk and upside.
Glaukos stock at a glance
GKOS Price
$245.72
1w %
9.5%
1y %
167.64%
5y %
401.47%
P/E
-83.29x
P/B
20.28x
P/S
21.04x
PEG
N/A
Revenue
$690.33M
Earnings
-$169.80M
Fore. Rev. Growth
22.17%
Fore. Earn. Growth
N/A
Market Cap
$14.55B
Next Earnings
N/A
Next Dividend
N/A
GKOS Due Diligence Checks
WallStreetZen was created to help everyday investors do more accurate fundamental analysis in minutes instead of hours.
Total GKOS debt is lower than 5 years ago, relative to shareholder equity.
GKOS has a low debt to equity ratio of 0.37.
There are more short-term assets than long-term liabilities on the GKOS balance sheet.
There are more short-term assets than short-term liabilities on the GKOS balance sheet.
GKOS's operating cash flow of $47.71M allows it to safely service it's debt of $101.98M.
Failed Health Checks:
GKOS earnings of -$169.70M is not enough to cover its interest payments.
GKOS profit margin has gone down from -18.6% to -24.6% in the past year.
Is Glaukos stock a Buy, Hold, or Sell, according to analysts?
Out of 12 Wall Street analysts who give forecasts on GKOS, the consensus analyst rating on Glaukos is a Strong Buy
It's important to keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent GKOS Analyst Recommendations
Adam Maeder, a top 21% analyst from Piper Sandler reiterates GKOS with a strong buy rating and raises their GKOS price target from $195.00 to $240.00, on Oct 29, 2026.
Tom Stephan, a top 40% analyst from Stifel Nicolaus maintains GKOS with a strong buy rating and raises their GKOS price target from $190.00 to $225.00, on Oct 29, 2026.
Ryan Zimmerman, a top 7% analyst from BTIG maintains GKOS with a strong buy rating and raises their GKOS price target from $205.00 to $234.00, on Oct 29, 2026.
BTIG's Ryan Zimmerman raised their price target on Glaukos (NYSE: GKOS) by 14.1% from $205 to $234 on 2026/10/29. The analyst maintained their Strong Buy rating on the stock.
The quarter's "outstanding" results addressed previous worries about competition in Corneal Health, thanks to the strong adoption of Epioxa, Zimmerman told readers.
David Saxon, a top 14% analyst from Needham maintains GKOS with a buy rating and raises their GKOS price target from $201.00 to $251.00, on Oct 29, 2026.
Michael Sarcone, a top 44% analyst from Jefferies maintains GKOS with a strong buy rating and raises their GKOS price target from $190.00 to $210.00, on Sep 22, 2026.
You can dive deeper into what analysts are forecasting on the Glaukos stock forecast page.
GKOS Trading Indicators
SMA10
237.66
SMA20
213.52
SMA50
184.62
SMA100
175.29
SMA200
147.26
MACD
19.13
MACD Signal
17
MACD Histogram
2.13
RSI
68.68
Stochastic %K
89.03
Stochastic %D
85.54
StochRSI %K
28.55
StochRSI %D
27.35
GKOS Performance Metrics
Last year, GKOS revenue was $690.33M. In the last 5 year, GKOS's revenue has gone up by 18.62% per year. This was faster than the Medical Devices industry average of 8.22%.
No, Glaukos doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your GKOS purchase
There are two primary types of orders:
Market order: A market order is an order to buy or sell a security at the best possible price. Market orders are usually the best for newer investors.
Limit order: A limit order is an order to buy or sell a stock at a specific price (or better). If you want to be sure you're buying or selling at a specific dollar amount limit, place a limit order.
Press the Open Trade button and eToro will execute the order.
If you require additional assistance buying stocks on eToro, click the how to video below:
As of Nov 13, 2026, it costs $245.72 to buy one share of Glaukos stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $100, you can buy 0.407 shares of GKOS.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.